Common warts that have failed to clear with initial treatment, or that have recurred after a prior course of management, present a distinct clinical challenge. These refractory and recurrent cases require a step-up approach beyond standard first-line care.
The protocol for this scenario centres on local intralesional injection therapy — agents delivered directly into the wart tissue at structured intervals. Multiple injectable agents have evidence supporting their use in this refractory and recurrent setting.
The specific agents, their selection criteria, and the treatment schedule are detailed in the full structured protocol.Complete clearance of warts at 4 weeks.
Complete clearance at 4 weeksLocal injections with bleomycin, 5-Fluorouracil (5-FU), and cidofovir are suggested for refractory and recurrent common warts.
A case-series study showed that after an average of 2.61 treatment cycles with intralesional injection of bleomycin (therapeutic dose at 3 U/ml and treatment interval at 3–4 weeks), all of the 250 periungual and subungual warts in 80 patients of whom 26 (32.50%) patients were either with no response to or recurrence after previous treatments were cleared and 65 (81.25%) patients experienced moderate pain during the treatment sessions, 155 (62.00%) treatment sites had transit dyspigmentation, and 3 (1.20%) treatment sites experienced reversible necrosis.
A prospective study reported that the cure rate of common warts with the injection of 5-FU, lidocaine, and epinephrine mixture (50 mg/ml 5-FU plus with lidocaine and epinephrine mixture at a ratio of 4:1) was higher than that of saline control (64.70% vs. 35.30%, p<0.05).
The result showed that lesional injection with 15 mg/ml cidofovir once a month, on average of 3.2 sessions, cleared relapsed and refractory warts in 276 of 280 patients.
The clinical criteria for cure of warts are complete clearance of lesions at 4 weeks and no recurrence for at least 6 months.
View source ↗